 Heidelberg, Germany, Novembe r 10 , 2020 Affimed N.V. Nasdaq: AFMD, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the three and nine months ended September 30, 2020 and provided an update on clinical and corporate progress. 